News Search Results
Mar 10, 2026, 11:00 ET Amyris, Inc. Launches New Production Line at Brazil Precision Fermentation Plant
take products to the next level of performance.Amyris was founded in 2003 with a bold humanitarian vision to transform drug access using biotechnology. Now, with over two decades of proven commercial success, our proprietary platform is redefining the precision, consistency, and sustainability
More news about: Amyris, Inc.
Mar 10, 2026, 10:40 ET Frontier RNG's START AgriTech Returns for Fourth Cohort in the U.S. Southwest
Tech University, Haifa Group, and the Ramat HaNegev Regional Council and Ramat HaNegev R&D Center, together with the College of Agriculture, Biotechnology & Natural Resources at the University of Nevada, Reno, with support from leading financial, academic, and public-sector partners including JPMorgan,
More news about: Frontier RNG
Mar 10, 2026, 10:25 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
BOSTON, March 10, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces
More news about: Skyhawk Therapeutics
Mar 10, 2026, 10:03 ET Sugar Substitutes Market to Surpass USD 11 Bn by 2031 as Demand for Low-Sugar Foods Accelerates, Says Mordor Intelligence
labeling expectations while maintaining sweetness intensity.Biotech Innovation Accelerates Production EfficiencyAdvances in biotechnology are reshaping supply chains across the sugar substitutes industry. Precision fermentation and metabolic engineering technologies are enabling the
More news about: Mordor Intelligence Private Limited
Mar 10, 2026, 10:02 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
BOSTON, March 10, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces
More news about: Skyhawk Therapeutics
Mar 10, 2026, 09:00 ET TRIANGLE INSIGHTS GROUP BY VALERIS ANNOUNCES APPOINTMENT OF ERIN SOLANO TO PARTNER
meaningful commercial success for her clients. She possesses diverse experience in strategic consulting for large pharma companies, early stage/start-up biotechnology companies, and medical supply and device manufacturers. She has a proven track record in US, global, and affiliate market access strategy, pricing
More news about: Valeris
Mar 10, 2026, 08:56 ET CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose
SEATTLE, March 10, 2026 /PRNewswire/ -- CounterX Therapeutics, a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the execution
More news about: CounterX Therapeutics
Mar 10, 2026, 08:50 ET Draper's LEAP Valve Demonstrates Spontaneous "Growth" in Preclinical Studies
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Mar 10, 2026, 08:03 ET Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis
Genomic Intelligence Platform and submitted to ClinVar, the widely used public archive of human genetic variants hosted by the National Center for Biotechnology Information (NCBI). Fabry disease is a rare, X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (α-Gal A),
More news about: Genomenon
Mar 10, 2026, 08:00 ET Origin Agritech Launches "Aoyun 2026" New Variety Promotion Program to Drive Commercialization of Next-Generation Seed Varieties
first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Mar 10, 2026, 07:30 ET Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 10, 2026, 07:00 ET Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea
The new Gateway Labs site will serve as a hub to support early-stage and emerging biotechnology companies, as they advance scientific research toward development and manufacturing. The facility will feature flexibly designed laboratory space
More news about: Samsung Biologics
Mar 10, 2026, 07:00 ET Novella names Antonio Martinez Descalzo as CEO to Lead Expansion
concludes.About Novella Novella Innovative Technology is a biotechnology company pioneering fruit- and vegetable-derived cell complexes for clean, intelligent, and sustainable wellness solutions. Leveraging its proprietary
More news about: Novella
Mar 10, 2026, 06:59 ET Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
WALTHAM, Mass., March 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
Mar 10, 2026, 06:30 ET Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European Patent
More news about: Immunic, Inc.
Mar 10, 2026, 06:00 ET Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
through 2044 (excluding potential patent extensions).About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Mar 10, 2026, 01:29 ET FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%
much as 50 percent — roughly $20 million per program2 — opening a market long dominated by large pharmaceutical firms to smaller biotechnology companies.
More news about: Professor Sarfaraz K. Niazi
Mar 09, 2026, 20:42 ET Singapore Lab-Grown Meat Market to Experience Strong Growth at 15.92% CAGR Through 2032, Fueled by Sustainable Protein Demand | MarkNtel Advisors
Technology InnovationSingapore's cultivated meat ecosystem continues to benefit from increasing investments by venture capital firms, biotechnology investors, and global food companies seeking to advance cellular agriculture technologies. These investments are supporting research and development
More news about: MarkNtel Advisors
Mar 09, 2026, 18:55 ET Myosin Therapeutics Invited to Present at Two South Florida Life Sciences Conferences
-- Myosin Therapeutics today announced it has been invited to present at two upcoming South Florida life sciences events highlighting emerging biotechnology innovation and regional industry growth. On March 10, the company will participate in the Investival Showcase: South Florida – The Rising Life
More news about: Myosin Therapeutics Inc.
Mar 09, 2026, 16:23 ET Cell and Gene Therapy Manufacturing Market to Reach USD 146.2 Billion by 2032 Amid Rising Demand for Personalized Therapies, Viral Vector Capacity, and Automated Bioprocessing - Credence Research
Germany, the U.K., and France are leading market expansion, supported by favorable EMA frameworks, strong biotechnology research activity, and increasing partnerships between biotechnology companies and contract manufacturing organizations.Asia Pacific is expected to witness substantial
More news about: Credence Research Inc.
Mar 09, 2026, 11:34 ET bitBiome and Kyoritsu Seiyaku Announce Strategic Collaboration in Animal Health and Nutrition
Under this collaboration, bitBiome and Kyoritsu Seiyaku will co-develop products utilizing advanced biotechnology for applications in animal health and nutrition. bitBiome will lead the development of products and manufacturing processes, while working to commercialize
More news about: bitBiome
Mar 09, 2026, 11:07 ET PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that the recently reported long-term
More news about: NeuroSense
Mar 09, 2026, 11:01 ET CSL announces expansion of Illinois plasma therapy manufacturing facility
the critical role Illinois plays in producing the life-saving therapies patients depend on," said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO). "Our state's combination of scientific talent, manufacturing expertise, and leading research institutions makes
More news about: CSL
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
for treatment-resistant depression, enrolling 142 patients. AtaiBeckley recently redomiciled to the United States, was added to the NASDAQ Biotechnology Index, and reports a cash runway extending into 2029, providing financial stability through multiple anticipated clinical catalysts.Definium
More news about: USA News Group
Mar 09, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued a
More news about: Anixa Biosciences, Inc.